> Alantos Pharmaceuticals of Cambridge, MA has signed a collaboration deal for its lead compound, ALS 2-0426 for Type 2 diabetes, with France's Servier. Alantos stands to gain $75 million in up front fees and milestones. Release [1]
> Millipore has opened its $50 million R&D center in Bedford, MA. Release [2]
> Chutes & Ladders: Threshold Pharmaceuticals [3] CFO and COO Michael Ostrach is resigning his posts. Report [4]
> Organon [5] and BrainCells [6] say they will collaborate on the development of new CNS drugs. Report [7]
> ProNAi Therapeutics has arranged $6.65 million in bridge financing. Report [8]
> Axial Biotech has raised a small round of venture capital. Report [9]
> Wyeth has extended a deal that gives it access to Affymetrix's GeneChip microarray technology by three years. Report [10]
And Finally… Inspired by a website, a rush of patients complaining of the same mysterious symptoms has spurred the CDC to see if two clusters are indeed the result of Morgellons disease. Article [11]
Links:
[1] http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-24-2006/0004458064&EDATE=
[2] http://www.pharmalive.com/News/index.cfm?articleid=383761&categoryid=54
[3] http://www.fiercebiotech.com/search/node/Threshold+Pharmaceuticals
[4] http://sanfrancisco.bizjournals.com/sanfrancisco/stories/2006/10/23/daily8.html?jst=b_ln_hl
[5] http://www.fiercebiotech.com/search/node/Organon+
[6] http://www.fiercebiotech.com/search/node/BrainCells+
[7] http://www.forbes.com/business/feeds/afx/2006/10/23/afx3111378.html
[8] http://feed.insnews.org/v-cgi/feeds.cgi?feedid=150&story_id=2252897
[9] http://www.techrockies.com/story/0005933.html
[10] http://today.reuters.com/news/articleinvesting.aspx?view=CN&storyID=2006-10-24T121441Z_01_WEN7712_RTRIDST_0_HEALTH-WYETH-URGENT.XML&rpc=66&type=qcna
[11] http://www.nytimes.com/2006/10/24/health/24cons.html?ref=health